<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3148">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05120193</url>
  </required_header>
  <id_info>
    <org_study_id>CP-00009</org_study_id>
    <nct_id>NCT05120193</nct_id>
  </id_info>
  <brief_title>Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System</brief_title>
  <acronym>SPHERE-PerAF</acronym>
  <official_title>Treatment of Persistent Atrial Fibrillation With the Sphere-9 Mapping and Ablation Catheter and the Affera Mapping and Ablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affera, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized clinical evaluation of the Sphere-9 Mapping&#xD;
      and Ablation Catheter with the Affera Mapping and Ablation System. Subjects will be randomly&#xD;
      assigned 1:1 to receive treatment with either the Sphere-9 Mapping and Ablation Catheter and&#xD;
      the Affera Mapping and Ablation System (investigational device) or the THERMOCOOL SMARTTOUCH®&#xD;
      SF radiofrequency ablation catheter (control device).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Subjects will be blinded to treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects with a primary adverse event</measure>
    <time_frame>180 Days</time_frame>
    <description>The primary safety endpoint is the incidence of the following device- or procedure-related serious adverse events (SAEs) following the index ablation procedure:&#xD;
Within 7 days:&#xD;
Death&#xD;
Myocardial infarction&#xD;
Phrenic nerve paralysis&#xD;
Transient ischemic attack (TIA)&#xD;
Stroke/cerebrovascular accident (CVA)&#xD;
Thromboembolism&#xD;
Major vascular access complications / bleeding&#xD;
Heart block&#xD;
Gastroparesis&#xD;
Severe pericarditis&#xD;
Hospitalization due to cardiovascular or pulmonary AE&#xD;
Within 30 days:&#xD;
• Cardiac tamponade / perforation&#xD;
Within 90 days:&#xD;
• Atrio-esophageal fistula&#xD;
Within 180 days:&#xD;
• Pulmonary vein stenosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of subjects free from primary effectiveness failure</measure>
    <time_frame>12 months</time_frame>
    <description>The primary effectiveness endpoint is freedom from documented recurrence of atrial tachyarrhythmias excluding the 90-day blanking period. The following are also considered primary effectiveness endpoint failures:&#xD;
Acute procedural failure&#xD;
Non-study catheter failure&#xD;
Repeat ablation/surgery failure&#xD;
AAD failure&#xD;
Cardioversion failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy application time</measure>
    <time_frame>Day 0</time_frame>
    <description>Total energy application time during the index ablation procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment time</measure>
    <time_frame>Day 0</time_frame>
    <description>Time from start to end of energy delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>Day 0</time_frame>
    <description>Time from start to end of venous access</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Sphere-9 Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sphere-9™ Mapping and Ablation Catheter; Affera Mapping System; Affera Ablation System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THERMOCOOL SMARTTOUCH SF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>THERMOCOOL SMARTTOUCH® SF Catheter; SMARTABLATE® System; CARTO® 3 System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mapping and Ablation</intervention_name>
    <description>Minimally invasive catheter mapping and ablation procedure</description>
    <arm_group_label>Sphere-9 Catheter</arm_group_label>
    <arm_group_label>THERMOCOOL SMARTTOUCH SF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic PerAF documented by (1) a physician's note indicating symptoms consistent&#xD;
             with AF sustained longer than 7 days but less than 12 months; AND either (2a) a&#xD;
             24-hour Holter documenting continuous AF within the past year OR (2b) two&#xD;
             electrocardiograms (from any form of rhythm monitoring, including consumer devices)&#xD;
             taken at least 7 days apart within the past year, each showing continuous AF.&#xD;
&#xD;
          2. Failure or intolerance of at least one Class I or III anti-arrhythmic drug (AAD).&#xD;
&#xD;
          3. Suitable candidate for catheter ablation.&#xD;
&#xD;
          4. Adults aged 18 - 75 years.&#xD;
&#xD;
          5. Willing and able to comply with all baseline and follow-up evaluations for the full&#xD;
             length of the study.&#xD;
&#xD;
          6. Willing and able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Continuous AF lasting for 12 months or longer.&#xD;
&#xD;
          2. AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication, or&#xD;
             other reversible or non-cardiac cause.&#xD;
&#xD;
          3. Previous left atrial ablation or surgical procedure (including septal closure or left&#xD;
             atrial appendage closure).&#xD;
&#xD;
          4. Valvular cardiac surgical/percutaneous procedure (e.g., ventriculotomy, atriotomy, and&#xD;
             valve repair or replacement and presence of a prosthetic valve).&#xD;
&#xD;
          5. Any carotid stenting or endarterectomy.&#xD;
&#xD;
          6. Any cardiac procedure (surgical or percutaneous) or percutaneous coronary intervention&#xD;
             within the 90 days prior to the initial procedure.&#xD;
&#xD;
          7. Coronary artery bypass graft (CABG) procedure within the 6 months prior to the initial&#xD;
             procedure.&#xD;
&#xD;
          8. Awaiting cardiac transplantation or other cardiac surgery within the 12 months&#xD;
             following the initial ablation procedure.&#xD;
&#xD;
          9. Presence of a permanent pacemaker, biventricular pacemaker, or any type of implantable&#xD;
             cardiac defibrillator (with or without biventricular pacing function).&#xD;
&#xD;
         10. Documented thromboembolic event (stroke or transient ischemic attack) within 6 months&#xD;
             (180 days) prior to the initial ablation procedure.&#xD;
&#xD;
         11. Documented left atrial thrombus on imaging.&#xD;
&#xD;
         12. History of blood clotting or bleeding abnormalities.&#xD;
&#xD;
         13. Any condition contraindicating chronic anticoagulation.&#xD;
&#xD;
         14. Myocardial infarction (MI) within the 3 months (90 days) prior to the initial&#xD;
             procedure.&#xD;
&#xD;
         15. Body mass index &gt;40 kg/m2.&#xD;
&#xD;
         16. Left atrial diameter &gt;55 mm (anterioposterior).&#xD;
&#xD;
         17. Diagnosed atrial myxoma.&#xD;
&#xD;
         18. Left ventricular ejection fraction (EF) &lt; 35%.&#xD;
&#xD;
         19. Uncontrolled heart failure or NYHA Class III or IV heart failure.&#xD;
&#xD;
         20. Rheumatic heart disease.&#xD;
&#xD;
         21. Hypertrophic cardiomyopathy.&#xD;
&#xD;
         22. Unstable angina.&#xD;
&#xD;
         23. Moderate to severe mitral valve stenosis.&#xD;
&#xD;
         24. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥&#xD;
             50%, and/or effective regurgitant orifice area ≥ 0.40cm2).&#xD;
&#xD;
         25. Primary pulmonary hypertension.&#xD;
&#xD;
         26. Significant restrictive or obstructive pulmonary disease or chronic respiratory&#xD;
             condition.&#xD;
&#xD;
         27. Renal failure requiring dialysis.&#xD;
&#xD;
         28. History of severe Gastroesophageal Reflux Disease (GERD) requiring surgical and/or&#xD;
             mechanical intervention.&#xD;
&#xD;
         29. Acute illness, active systemic infection, or sepsis.&#xD;
&#xD;
         30. Contraindication to both computed tomography and magnetic resonance angiography.&#xD;
&#xD;
         31. Significant congenital anomaly or medical problem that, in the opinion of the&#xD;
             investigator, would preclude enrollment in this study or compliance with follow-up&#xD;
             requirements or would impact the scientific soundness of the clinical study results.&#xD;
&#xD;
         32. Any woman known to be pregnant or breastfeeding, or any woman of childbearing&#xD;
             potential who is not on a reliable form of birth regulation method or abstinence.&#xD;
&#xD;
         33. Current or anticipated participation in any other clinical study of a drug, device, or&#xD;
             biologic during the duration of the study not pre-approved by the Sponsor.&#xD;
&#xD;
         34. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular&#xD;
             access, catheter introduction, or manipulation.&#xD;
&#xD;
         35. Known drug or alcohol dependency.&#xD;
&#xD;
         36. Life expectancy less than 12 months.&#xD;
&#xD;
         37. Vulnerable subject (such as a prisoner or handicapped or mentally disabled person).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meital Mazor, PhD</last_name>
    <phone>857-3044030</phone>
    <email>clinical_trials@affera.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

